Citius Pharmaceuticals Inc CTXR 深 滬
已收盤 01-09 16:00:00 美东时间
0.8877
-0.012
-1.37%
華盛通- 最 高0.90
- 今 開0.89
- 成交量 28.22万股
- 最 低 0.8311
- 昨 收 0.90
- 總市值 991.96万
- 52周最高 3.40
- 市盈率 靜 --
- 換手率 2.53%
- 52周最低 0.63
- 委 比 81.76%
- 總股本 1117.45万
- 歷史最高 137.25
- 量 比 0.79
- 振 幅 7.66%
- 歷史最低 0.63
- 每 手 1
- 風險率 0.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Pharmaceuticals (CTXR) Surges 22% After Hours — Here's Why
Citius Pharmaceuticals shares jumped 22.12% after hours following the commercial launch of its LYMPHIR therapy and a fiscal 2025 business update.
2025-12-24 14:56
Citius Pharma Q4 EPS $(0.11) Beats $(0.43) Estimate
Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.43) by 74.42 percent. This is a 93.6 percent increase over losses of $(1.72) per share from the
2025-12-24 05:36
Citius Oncology Subsidiary, Citius Oncology, Launches Cancer Immunotherapy, LYMPHIR, In The U.S. In December 2025 For The Treatment Of Adult Patients With Relapsed Or Refractory Stage I-III CTCL After At Least One Prior Systemic Therapy; Co. Raised ~ $61M In Gross Proceeds From Capital Raises
Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported
2025-12-24 05:36
Citius Pharmaceuticals GAAP EPS of -$3.38
Citius Pharmaceuticals press release (CTXR): FY GAAP EPS of -$3.38. Cash and cash equivalents of $4.3 million as of September 30, 2025; Citius Pharma did not report revenues for the year; R&D expenses...
2025-12-24 05:35
Citius Oncology announces $18 million registered direct offering
Citius Oncology (CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals (CTXR), announced on Tuesday that it has entered into a definitive agreement with a single healthcare-focused investor...
2025-12-09 21:49
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
2025-12-05 08:35
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
2025-12-05 02:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Clene (NASDAQ:CLNN) stock increased by 10.0% to $7.94 during Wednesday'...
2025-12-04 05:06
Citius Pharma Subsidiary Announces Commercial Launch Of LYMPHIR, IL-2 Receptor-Directed Fusion Protein For r/r Stage I–III Cutaneous T-Cell Lymphoma Treatment
Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ:CTXR), today announced the commercial launch of LYMPHIR™
2025-12-02 01:06
Citius Oncology Collaborates With Verix To Further Leverage Tovana Platform To Support Anticipated Q4 2025 U.S. Commercialization Of FDA Approved LYMPHIR For CTCL Treatment
Leading edge artificial intelligence and machine learning platform supports enhanced salesforce targeting and engagement for cutaneous T-cell lymphoma immunotherapy launchCRANFORD, N.J., Nov. 21, 2025 /PRNewswire/
2025-11-21 21:41
